Skip to main content

Table 2 Key patient characteristics at baseline for all studies

From: Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis

Author

Treatment

% Male1

Age (sd or range)2

% Current smoker3

% Severe4

% on ICS5

FEV1 mean L (sd)6

Reversibility post-SABA (sd)7

MOITA, 2008

Tiotropium; 18 μg; OD

NR

NR

28 %

NR

NR

NR

NR

Placebo

NR

NR

25 %

NR

NR

NR

NR

VERKINDRE, 2006

Tiotropium; 18 μg; OD

94 %

61 (9.5)

24 %

95 %

NR

1.05 (0.4)

NR

Placebo

94 %

60 (10.2)

33 %

94 %

NR

1.08 (0.3)

NR

COVELLI, 2005

Tiotropium; 18 μg; OD

66 %

66 (8.9)

40 %

77 %

54 %

1.06 (0.4)

NR

Placebo

49 %

63 (9.2)

37 %

80 %

58 %

0.99 (0.4)

NR

CASABURI, 2000

Tiotropium; 18 μg; OD

67 %

65 (8.6)

NR

79 %

NR

1.04 (0.4)

NR

Placebo

63 %

66 (9.0)

NR

80 %

NR

1.00 (0.4)

NR

CASABURI, 2002

Tiotropium; 18 μg; OD

67 %

65 (9.0)

NR

79 %

44 %

1.04 (0.4)

NR

Placebo

63 %

65 (9.0)

NR

80 %

40 %

1.00 (0.4)

NR

NIEWOEHNER, 2005

Tiotropium; 18 μg; OD

98 %

68 (8.7)

29 %

87 %

61 %

1.04 (0.4)

NR

Placebo

99 %

68 (8.5)

30 %

87 %

58 %

1.04 (0.4)

NR

CHAN, 2007

Tiotropium; 18 μg, OD

59 %

68 (8.7)

32 %

79 %

66 %

0.97 (0.4)

NR

Placebo

61 %

67 (9.1)

30 %

78 %

71 %

0.96 (0.4)

NR

TONNEL, 2008

Tiotropium; 18 μg: OD

87 %

65 (9.7)

24 %

58 %

38 %

1.38 (0.4)

NR

Placebo

85 %

64 (10.1)

30 %

62 %

36 %

1.35 (0.5)

NR

HANANIA, 2003

Salmeterol; 50 μg; BID

58 %

64 (42–87)

51 %

75 %

0 %

1.25 (0.4)

NR

Placebo

68 %

65 (40–81)

47 %

75 %

0 %

1.29 (0.4)

NR

MAHLER, 2002

Salmeterol; 50 μg; BID

64 %

64 (40–84)

46 %

NR

31 %

1.23 (NR)

NR

Placebo

75 %

64 (44–90)

54 %

NR

18 %

1.31 (NR)

NR

VAN RUTTEN, 1999

Salmeterol; 50 μg; BID

89 %

65 (5.8)

NR

73 %

81 %

1.30 (0.4)

NR

Placebo

86 %

63 (7.4)

NR

77 %

76 %

1.30 (0.4)

NR

CELLI, 2003

Salmeterol; 50 μg; BID

80 %

64 (8.7)

NR

73 %

NR

1.30 (0.5)

NR

Placebo

71 %

65 (8.7)

NR

69 %

NR

1.35 (0.5)

NR

GROSS, 2008

Formoterol; 12 μg; BID

54 %

63 (9.4)

54 %

70 %

23 %

1.30 (0.4)

15 % (NR)

Placebo

57 %

64 (9.2)

54 %

64 %

19 %

1.36 (0.5)

11 % (NR)

ROSSI, 2002

Formoterol; 12 μg; BID

87 %

63 (NR)

NR

NR

NR

1.36 (NR)

NR

Placebo

80 %

63 (NR)

NR

NR

NR

1.40 (NR)

NR

DAHL, 2001

Formoterol; 12 μg; BID

74 %

64 (8.8)

46 %

63 %

47 %

1.33 (0.5)

NR

Placebo

79 %

63 (9.0)

49 %

68 %

54 %

1.29 (0.4)

NR

BRIGGS, 2005

Tiotropium; 18 μg; OD

65 %

64 (8.6)

35 %

86 %

54 %

1.05 (0.4)

14 % (NR)

Salmeterol; 50 μg; BID

68 %

65 (7.8)

37 %

84 %

47 %

1.04 (0.4)

18 % (NR)

B2334, 2008 DAHL, 2010

Indacaterol; 300 μg; OD

80 %

64 (8.6)

42 %

46 %

56 %

1.48 (0.5)

12 % (13 %)

Formoterol; 12 μg; BID

80 %

64 (8.5)

41 %

44 %

51 %

1.50 (0.5)

12 % (13 %)

Placebo

82 %

63 (8.3)

40 %

45 %

52 %

1.52 (0.5)

13 % (13 %)

B2335S, 2008 DONOHUE, 2010

Indacaterol; 150 μg; OD

62 %

63 (9.4)

45 %

38 %

38 %

1.52 (0.5)

16 % (15 %)

Indacaterol; 300 μg; OD

63 %

63 (9.3)

45 %

38 %

37 %

1.53 (0.5)

15 % (15 %)

Tiotropium; 18 μg; OD

65 %

64 (8.8)

45 %

43 %

35 %

1.45 (0.5)

16 % (18 %)

Placebo

61 %

64 (8.9)

46 %

40 %

40 %

1.51 (0.5)

16 % (18 %)

B2336, 2009 KORNMANN, 2010

Indacaterol; 150 μg; OD

72 %

63 (8.7)

46 %

42 %

45 %

1.48 (0.5)

12 % (15 %)

Salmeterol; 50 μg; BID

75 %

63 (9.2)

46 %

43 %

46 %

1.48 (0.5)

11 % (14 %)

Placebo

77 %

64 (8.6)

45 %

44 %

40 %

1.46 (0.5)

13 % (16 %)

B2346, 2008 FELDMAN, 2010

Indacaterol; 150 μg; OD

51 %

63 (9.9)

51 %

40 %

29 %

1.50 (0.5)

16 % (17 %)

Placebo

54 %

63 (9.6)

53 %

38 %

34 %

1.50 (0.5)

17 % (19 %)

B2354, 2010

Indacaterol; 75 μg; OD

55 %

64 (8.3)

44 %

41 %

43 %

NR

15 % (13 %)

Placebo

54 %

64 (9.4)

44 %

44 %

48 %

NR

17 % (14 %)

B2355, 2010

Indacaterol; 75 μg; OD

52 %

61 (9.8)

58 %

30 %

40 %

NR

18 % (17 %)

 

Placebo

56 %

62 (9.9)

60 %

45 %

35 %

NR

16 % (14 %)

  1. 1 % male = proportion of patients who were male; NR = not reported; 2Age (sd or range) = average and standard deviation or age range where reported; SE = standard error; 3 % Current smokers = proportion of patients who were current smokers as opposed to ex-smokers; 4 % severe (very severe) = proportion of patients who had severe or very severe COPD as classified by GOLD guidelines (as opposed to mild or moderate COPD); 5 % on ICS = proportion of patients taking concomitant inhaled corticosteroids during trial period; 6FEV1 mean L = average forced expiratory volume in 1 second. Postbronchodilator FEV1 measured 30 min after salbutamol 400 mg inhalation (INVOLVE, INLIGHT-1/2) or albuterol 360 mg inhalation (INHANCE); 7SABA = short-acting β2-agonis. Reversibility was calculated as the difference between the prebronchodilator and postbronchodilator values of FEV1 (in litres) as a percentage of the prebronchodilator value.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us